Trials / Conditions / Advanced Non-squamous Non-small-cell Lung Cancer

Advanced Non-squamous Non-small-cell Lung Cancer

14 registered clinical trials studyying Advanced Non-squamous Non-small-cell Lung Cancer — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Emulation of the CheckMate 017/057 (NCT01642004 and NCT01673867) Trials Using Specialty Oncology Electronic He NCT07485166	Brigham and Women's Hospital	—
Recruiting	A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advan NCT06585488	BeiGene	Phase 1
Recruiting	Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint NCT06463665	Genelux Corporation	Phase 2
Recruiting	JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung NCT06416410	Allist Pharmaceuticals, Inc.	Phase 3
Not Yet Recruiting	Efficacy and Safety of Nab-paclitaxel-Lenvatinib-Pembrolizumab as Second-line Treatment in Advanced NSCLC Pati NCT06028633	Peking University First Hospital	Phase 2
Unknown	A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Che NCT05346952	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 3
Unknown	First-Line Treatment for Advanced Non-squamous Non-Small-Cell Lung Cancer With Negative Driver Gene: a Single- NCT05648071	Qianfoshan Hospital	Phase 3
Completed	A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC NCT04959981	Erasca, Inc.	Phase 1
Unknown	Efficacy and Safety of Use of Platinum Based Doublet Chemotherapy Plus Antiangiogenesis and Immune Checkpoint NCT04137588	Peking University Cancer Hospital & Institute	—
Unknown	A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSC NCT04416035	Zhejiang Teruisi Pharmaceutical Inc.	Phase 3
Withdrawn	Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small Cell Lung Cancer Patien NCT03792503	Xinqiao Hospital of Chongqing	Phase 4
Withdrawn	Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced Non-squamous Non-small Cell L NCT03190239	Xinqiao Hospital of Chongqing	Phase 2
Completed	Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamou NCT01063283	University of Chicago	N/A
Completed	Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non- NCT01204307	Chang Gung Memorial Hospital	Phase 2